Insulin delivery device for type 2 patients gets EU approval

A new insulin delivery system for type 2 diabetics has been approved for sale by European regulators after meeting safety and efficacy requirements.
Developed by Swiss firm CeQur SA, the PaQ device is a small discreet, wearable product that combines a disposable insulin-infuser reservoir with a reusable insulin monitor. It delivers up to three days’ worth of basal, as well as on-demand bolus, insulin subcutaneously through a fine, soft tube or cannula.
Insulin treatment is more common amongst people with type 1 diabetes. However, an increasing number of type 2 diabetes sufferers also require intensive insulin therapy to help improve blood sugar control.
CeQur estimate that more than 30 million people across the 27 European Union nations take regular daily injections of insulin as part of their diabetes management, including a substantial number of type 2s.
But the company also predicts that half of all insulin-using patients intentionally skip doses at times when they find injecting to be embarrassing, painful, inconvenient, or disruptive.
By using continuous insulin-infusion technology, PaQ eliminates the need for multiple insulin shots, which the firm believes will help improve insulin adherence and reduce the risk of long-term diabetes complications.
Commenting on the CE Mark approval, CeQur founder and CEO, James Peterso, said: “This regulatory achievement demonstrates the quality of both the PaQ device and the internal processes we’ve put in place to move this unique, important product through development and into the marketplace.”